Are These 2 'Strong Buy' Rated Growth Stocks Buys Right Now?
With a market capitalization of $21 million, Ovid Therapeutics is a small clinical-stage biopharmaceutical company focused on developing treatments for rare neurological disorders. Ovid's business model is centered on central nervous system (CNS) disorders, which are a challenging therapeutic area. Its pipeline includes novel compounds in early- to mid-stage development that target epilepsy and other genetically based neurological disorders. OVID stock has fallen 67.6% year-to-date (YTD), compared to the S&P 500 Index's ($SPX) gain of 1.6%.
Dear Tesla Stock Fans, Mark Your Calendars for June 30
3 ETFs with Dividend Yields of 12% or Higher for Your Income Portfolio
This Options Tool Can Show You How to Trade Tesla Stock Ahead of Robotaxi Day
Get exclusive insights with the FREE Barchart Brief newsletter. Subscribe now for quick, incisive midday market analysis you won't find anywhere else.
Ovid currently has no FDA-approved products on the market. However, Wall Street analysts have called OVID a "Strong Buy," with all six analysts covering the stock rating it as such. Still, the company has also received a delisting notice from Nasdaq for failing to maintain the minimum bid price of $1.00 per share. Ovid has until Aug. 11, 2025, to regain compliance by maintaining a closing bid price of at least $1.00 for 10 consecutive trading days.
Ovid's pipeline is small in size but very targeted. The most closely watched candidate is OV329, a highly selective small-molecule inhibitor of GABA aminotransferase (GABA-AT). OV329 is intended to treat epilepsy that has not responded to previous treatments. In preclinical models, the candidate has shown promise in controlling seizures while causing fewer side effects than existing treatments such as vigabatrin. Ovid Therapeutics anticipates Phase 1 trial results in the third quarter of 2025.
The company has a good chance of its stock ticking upwards if the Phase 1 topline results for OV329 turn out positive. Ovid's other candidate is OV350, a next-generation KCC2 modulator that is also being tested in a Phase 1 trial. The company generated $130,000 in revenue from royalty agreements during Q1. At the end of the quarter, its cash, equivalents, and marketable securities totaled $43 million. This gives the company an estimated runway through the second half of 2026.
Ovid has received a 'Strong Buy' rating on Wall Street because of its rich pipeline of rare disease treatments. The stock may appeal to long-term aggressive investors who are comfortable with volatility and have a strong interest in innovative science. However, I believe investors should wait until Ovid either clears the $1 delisting threshold or proves its clinical strategy with positive results. Analysts have an average target price of $2.88 for the stock, which implies upside potential of 860% from current levels. The Street-high price estimate stands at $4 for OVID stock.
With a market cap of $609 million, Nuvation Bio is a clinical-stage biotech company that develops targeted oncology treatments for challenging cancers with limited treatment options. However, it may soon release a revenue-generating product to the market this year. NUVB stock is down 27.7% YTD, compared to the overall market gain.
Nuvation Bio's pipeline includes programs addressing a variety of oncology targets, including breast, ovarian, and lung cancer. Its pipeline currently consists of four core programs: taletrectinib (ROS1 inhibitor), NUV-1511 (drug-drug conjugate), safusidenib (brain-penetrant IDH1 inhibitor), and NUV-868 (BET inhibitor).
Taletrectinib, Nuvation's lead candidate for the treatment of ROS1+ and advanced non-small cell lung cancer, has already been approved in China and the United States. The company hopes to begin commercializing taletrectinib in mid-2025. In March, the firm secured $250 million in non-dilutive financing from Sagard Healthcare Partners, as well as $150 million in royalty financing and $50 million in debt, subject to approval. Nuvation also has the option to secure an additional $50 million in debt until June 30, 2026 if it completes its first commercial sale in the United States.
Safusidenib is currently in Phase 2 trials, and NUV-1511 is in Phase ½ trials. The company intends to provide updates for both during the second half of 2025. Nuvation ended Q1 with $461.7 million in cash, cash equivalents, and marketable securities. A favorable FDA decision could open up significant market opportunities for the company. Nuvation Bio's late-stage pipeline, strong cash position, and clear commercialization path make it an appealing biotech growth stock to buy right now. However, the company's ability to generate profits after commercialization may take years, making it an appropriate choice for those with a high risk tolerance and a longer investment horizon.
Overall, Wall Street rates NUVB stock a 'Strong Buy.' Of the seven analysts covering the stock, six rate Nuvation as a 'Strong Buy' while one recommends a 'Moderate Buy" rating. The average price target of $7.17 suggests that NUVB stock could rally around 258% over the next 12 months. The high price estimate of $10 suggests a gain of 400% over current levels.
On the date of publication, Sushree Mohanty did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Barchart.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Digital Trends
2 minutes ago
- Digital Trends
At last, a humanoid robot masters the chore we all hate
A couple of weeks ago, we watched in awe as Figure's humanoid robot grabbed clothes from a laundry basket before deftly depositing them in a washer. It was all very impressive. In a follow-up that offers a glimpse of a future where humans can finally ignore this wretched chore, Figure has shared another video showing the same robot folding freshly washed towels before placing them in a pile. Today we unveiled the first humanoid robot that can fold laundry autonomously Same exact Helix architecture, only new data — Figure (@Figure_robot) August 12, 2025 The California-based tech company said it's the first humanoid robot capable of folding laundry 'fully autonomously,' a statement that will surely cause millions of people around the world to call out at once: 'So where can I get one?' Well, more on that later. Recommended Videos To conduct the process, Figure 02 uses the same Helix Vision Language Action (VLA) model that the company has already deployed for industrial logistics tasks, but now with a new dataset for laundry folding. To be clear, the robot performs the laundry task without teleoperation or specialized hand-coded instructions, relying instead on an end-to-end neural network. As you can see, the robot uses multi-fingered hands to competently pick towels from a pile. It also performs different folding strategies, recovers from errors such as grabbing multiple towels at once, and carries out fine manipulations — just like a human. The video demonstrates real advances in one of the areas that robotics engineers still find extremely challenging: manipulation of objects, especially soft, flexible ones. Indeed, the robot's impressive ability to handle the humble towel looks like an exciting step toward such machines being able to cope with other non-rigid items, opening them up to a plethora of other tasks in a broader range of settings. 'Folding laundry sounds mundane for a person, but this is one of the most challenging dexterous manipulation tasks for a humanoid robot,' Figure said in a post on its website. 'Towels are deformable, constantly changing shape, bending unpredictably, and prone to wrinkling or tangling. There's no fixed geometry to memorize, and no single 'correct' grasp point. Even a slight slip of a finger can cause the material to bunch or fall. Success requires more than just seeing the world accurately — it demands fine, coordinated finger control to trace edges, pinch corners, smooth surfaces, and adapt in real time.' While Figure is currently focused on deploying its humanoid robot in industrial locations, it will — tantalizingly for all of those laundry haters out there — begin testing it in home settings this year. Figure has yet to mention pricing and other purchasing details for individual customers, so for the time being at least, the laundry will continue as a regular chore for most folks. But this humanoid robot certainly offers hope …
CBS News
3 minutes ago
- CBS News
Point Park University to house some students in Downtown Pittsburgh's Wyndham Grand hotel
Some incoming freshman at Point Park University will be staying in a hotel this fall. Point Park says it's anticipating one of its largest freshman classes in history and doesn't have enough room for all of them. A spokesperson for the university says some students will be staying at the Wyndham Grand hotel near Point State Park. "Enrollment has risen enough for the fall semester, particularly with first-year freshmen, and that's what caused us to seek a hotel partner," Point Park University spokesperson Lou Corsaro told the Post-Gazette. The school says the hotel is a five to six minute walk to class and students who stay in the hotel won't have to pay any extra fees. Most students at Point Park are expected to move onto campus between August 16 and August 23. Point Park's placing students in hotels comes as the University of Pittsburgh is also putting freshman students into off-campus hotels and apartments. 400 beds have been reserved for freshman students at off-campus apartments and at the Hampton Inn on Hamlet Street. Pitt says the facilities all meet the universities' standards for safety, amenities, and access to campus resources.
Bloomberg
3 minutes ago
- Bloomberg
Short Sellers Pile Into UK Bakery Chain Greggs as Growth Wanes
By and Lisa Pham Save Short sellers are betting against Greggs Plc at levels not seen since the global financial crisis, as the UK bakery chain struggles to convince investors that opening more shops will boost lackluster sales. Greggs stock out on loan — an indication of short interest — reached 9% of shares outstanding as of Tuesday, according to data from S&P Global Market Intelligence. That's the highest since March 2008, with the bulk of this year's activity occurring in the past four months.
